...
首页> 外文期刊>Expert opinion on pharmacotherapy >Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.
【24h】

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.

机译:纳地沙星:一种喹诺酮,用于局部治疗皮肤感染以及潜在使用其活性异构体WCK 771。

获取原文
获取原文并翻译 | 示例
           

摘要

Nadifloxacin is a potent, broad-spectrum, quinolone agent approved for topical use in acne vulgaris and skin infections in Japan. As exposure of pathogenic and colonising bacteria to antibiotics results in drug resistance, it is not desirable to use an important, broad-spectrum antibiotic, which belongs to a class of agents widely used systemically to treat a wide variety of infections, as a topically applied preparation. On this basis, nadifloxacin is not a good option for topical treatment of acne when other effective non-antibiotic treatments are available. Nadifloxacin has potential as a topical agent for short-term treatment of skin infections. The arginine salt of its (-)-(S)-isomer is being developed as a parenteral agent based on its potency against methicillin and quinolone-resistant Staphylococcus aureus.
机译:纳地沙星是一种有效的,广谱的喹诺酮药物,在日本已被批准用于寻常性痤疮和皮肤感染。由于致病菌和定殖细菌暴露于抗生素会导致耐药性,因此不希望使用重要的广谱抗生素,因为它属于局部应用,广泛用于全身性治疗各种感染制备。在此基础上,当可获得其他有效的非抗生素治疗方法时,纳地沙星不是局部治疗痤疮的好选择。纳地沙星有潜力作为短期治疗皮肤感染的局部用药。基于其对甲氧西林和耐喹诺酮类金黄色葡萄球菌的效力,正在开发其(-)-(S)-异构体的精氨酸盐作为肠胃外药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号